KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Change in Cash (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Change in Cash for 9 consecutive years, with -$9.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash fell 231.7% year-over-year to -$9.6 million, compared with a TTM value of -$15.0 million through Dec 2025, down 144.71%, and an annual FY2025 reading of -$15.0 million, down 144.71% over the prior year.
  • Change in Cash was -$9.6 million for Q4 2025 at Biocryst Pharmaceuticals, down from -$4.1 million in the prior quarter.
  • Across five years, Change in Cash topped out at $18.9 million in Q3 2024 and bottomed at -$149.6 million in Q1 2023.
  • Average Change in Cash over 3 years is -$17.9 million, with a median of -$5.0 million recorded in 2024.
  • The sharpest move saw Change in Cash surged 301.26% in 2024, then plummeted 231.7% in 2025.
  • Year by year, Change in Cash stood at -$40.0 million in 2023, then soared by 118.13% to $7.3 million in 2024, then tumbled by 231.7% to -$9.6 million in 2025.
  • Business Quant data shows Change in Cash for BCRX at -$9.6 million in Q4 2025, -$4.1 million in Q3 2025, and -$1.9 million in Q2 2025.